LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today confirmed receipt of a letter from PrimeStone Capital LLP (PrimeStone) to its Board of Directors and issued the following statement: “LivaNova welcomes open communication and values constructive input toward the goal of enhancing value for all LivaNova shareholders. The Company’s Board of Directors […]
Tag: PrimeStone Capital
Recent
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial and FDA Investigational Device Exemption Approval for Pivotal Trial
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
Popular
- No commented posts yet